GlaxoSmithKline PLC ADR (GSK) - Stock & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

GSK plc and its subsidiaries focus on researching, developing, and producing vaccines as well as specialty medicines to prevent and treat diseases worldwide, including in the UK and the US. They are involved in four main segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

The company's pharmaceutical products cover a range of therapeutic areas such as infectious disease, HIV, immunology, respiratory issues, and oncology. Previously known as GlaxoSmithKline plc, the company rebranded to GSK plc in May 2022, reflecting its continued dedication to health and wellness.

Established in 1715 with headquarters in Brentford, UK, GSK plc has a long-standing history of excellence in the pharmaceutical and healthcare industries. For more information, you can visit their website at https://www.gsk.com.

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GlaxoSmithKline PLC ADR (GSK) - Stock & Dividends

GSK Stock Overview

Market Cap in USD 85,680m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1986-07-09

GSK Stock Ratings

Fundamental 2.81
Dividend 4.20
Growth 5y 2.50
Rel. Performance vs Sector 0.91
Analysts 3.63
Fair Price Total Ret. 40.08
Fair Price DCF 27.16

GSK Dividends

Yield 12m 3.44%
Yield on Cost 5y 4.47%
Dividends CAGR 5y -7.73%
Payout Consistency 93.7%

GSK Growth Ratios

Growth 12m 28.58%
Growth Correlation 12m 52%
Growth Correlation 3m 80%
CAGR 5y 5.40%
CAGR / Mean Drawdown 0.41
Sharpe Ratio 12m 1.28
Alpha vs SP500 12m 8.53
Beta vs SP500 5y weekly 0.59
CAPM 6.86%
Average Daily Range 2m 1.17%
Regime Oscillator 82.85
Volatility GJR Garch 1y 16.54%
Price / SMA 50 7.49%
Price / SMA 200 18.07%
Current Volume 4041.1k
Average Volume 20d 4983.7k

External Links for GSK Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of GSK stocks?
As of February 29, 2024, the stock is trading at USD 42.34 with a total of 4,041,124 shares traded.
Over the past week, the price has changed by +1.94%, over one month by +9.46%, over three months by +19.96% and over the past year by +26.52%.
Why is GSK stock down?
Check with which Index or Commodity GSK has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return GSK Return S&P 500
1 Month 9.46% 3.05%
3 Months 19.96% 11.73%
12 Months 26.52% 29.22%
What is the forecast for GSK stock price target?
According to ValueRays Forecast Model, GSK GlaxoSmithKline PLC ADR will be worth about 43.8 in February 2025. The stock is currently trading at 42.34. This means that the stock has a potential upside of +3.35%.
Issuer Forecast Upside
Wallstreet Target Price 43.1 1.8%
Analysts Target Price 39.6 -6.4%
ValueRay Target Price 43.8 3.4%

GlaxoSmithKline PLC (GSK): A Comprehensive Overview

History of GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC, commonly known as GSK, is a British multinational pharmaceutical company with a rich history that dates back to the 18th century. The modern incarnation of GSK was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, but its roots can be traced to a small apothecary in London in 1715. Over the centuries, the company has been at the forefront of medical innovation, developing and distributing pharmaceuticals, vaccines, and health-related consumer products worldwide.

Core Business of GSK

GSK's core business revolves around the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. In pharmaceuticals, the company has a strong focus on immunology, oncology, and infectious diseases. The vaccine division of GSK is one of the largest in the world, providing vaccines for a multitude of diseases such as influenza, hepatitis, and rotavirus. Additionally, GSK's consumer healthcare segment offers a range of oral health, pain relief, respiratory, and nutritional products aimed at improving the quality of human life.

Side Businesses and Other Ventures

Besides its main pharmaceutical, vaccine, and consumer healthcare products, GSK is also involved in several side businesses and ventures. This includes partnerships with other pharmaceutical companies for research and development efforts, involvement in philanthropy through the GSK Foundation, and investment in biotechnology startups. The company's strategic focus on innovation and collaboration extends beyond traditional boundaries, aiming to address unmet medical needs and foster a healthier global community.

Current Market Status

As of the current market status, GSK remains a leading entity in the pharmaceutical industry, continually adapting to meet global health challenges. Despite facing competition, regulatory pressures, and the complexities of patent cliffs, GSK has maintained a solid market presence. The company's dedication to research and development has been pivotal in driving growth, with a strong pipeline of products anticipated to contribute to its future success. GSK's shares are actively traded on the New York Stock Exchange (NYSE) under the ticker GSK, where it is closely watched by investors for its performance, innovation, and resilience in the ever-changing pharmaceutical landscape.